Jill guides the design and implementation of HEOR, performance improvement, and program evaluation studies that drive opportunity identification and value creation for customers, including biopharmaceutical companies, health plans, provider networks, and patient advocacy groups.
Prior to joining Inovalon, Jill served as the director of analytics for specialty benefits with UnitedHealthcare, where she guided the development and deployment of claims-based analytical frameworks that supported health plan reporting and provider performance improvement initiatives across the enterprise. Jill has also held quantitative research appointments at America’s Health Insurance Plans and the Henry Jackson Foundation, supporting health services and clinical research studies that focused on identifying key drivers of commercial insurance trends, understanding variation in cost and utilization by site of service, and exploring the relationship between race and ethnicity and cancer treatment patterns and survivorship in Department of Defense beneficiaries.
Jill earned a master’s in epidemiology and biostatistics from George Mason University and a bachelor’s in physics from Longwood University with a minor in mathematics.
Healthcare Resource Utilization and Economic Burden Among Patients With COPD Following Cardiopulmonary Events: Evidence From the ABACOS OUTCOMES Study
Accepted for presentation at American Thoracic Society International Conference. Findings available upon request. Contact us for more information.
Reduction in COPD Exacerbations Following Prompt Triple Therapy Initiation After Hospital Discharge: Results from the MITOS EROS Discharge Study (U.S.)
Accepted for presentation at American Thoracic Society International Conference. Findings available upon request. Contact us for more information.
Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Before and After Completion of Specialist Visits: Results from the DUALITY Specialist
Accepted for presentation at American Thoracic Society International Conference. Findings available upon request. Contact us for more information.
Real-World Treatment Patterns, Discontinuation, and Treatment Switches in Patients With Generalized Myasthenia Gravis (gMG): A Retrospective Claims Analysis
Accepted for presentation at American Academy of Neurology. Findings available upon request. Contact us for more information.

Breathing Easier: Why Timing Matters in COPD Treatment
Discover how prompt COPD treatment significantly reduces flare-ups and severe heart risks, and improves patient outcomes.
Impact of Social Determinants of Health on Hepatocellular Carcinoma Surveillance, Treatment, and Healthcare Costs
This study of over 32,000 patients with HCC found that many people are not receiving these potentially life-saving screenings.